ATRC News and Press, AtriCure Inc. From 07/01/19

I introduced the idea that "Fear Of Missing Out" driven trade was afoot this past Friday and got in depth in my Sunday piece. You might want to start with the Sunday piece first to get the most out of this note. We are in a "Goldilocks" moment, let's embrace it, even if it goes against our...

I Hope You Started Buying Yesterday I've said this before but like a lot of what I do, it bears repeating. Stocks are the only item that loses attractiveness when the prices go down. Most people wait for a sale or they go to a discount store because they hate paying more for something if the...

AtriCure (ATRC) Q1 2019 Earnings Conference Call April 25, 2019 04:30 PM ET Company Participants Lynn Lewis - Investor Relations, Gilmartin Group Mike Carrel - President and Chief Executive Officer Andy Wade - Senior Vice President and Chief Financial Officer Conference Call P...

AtriCure (NASDAQ: ATRC ): Q1 GAAP EPS of -$0.15 beats by $0.09 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a...

The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibr...

Exact Sciences (NASDAQ: EXAS ) added to Goldman Sachs Conviction List. More news on: Exact Sciences Corporation, AtriCure, Inc., Collegium Pharmaceutical, Inc., Healthcare stocks news, , Read more ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host a conference call ...

Intuitive Surgical (NASDAQ: ISRG ) initiated with Buy rating and $630 (9% upside) price target. Shares up a fraction premarket. More news on: Intuitive Surgical, Inc., AtriCure, Inc., Quest Diagnostics Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18 th Annual Healthcare Conference in New York on Wednesday, April 10...